On January 12, Eli Lilly announced a joint venture with Nvidia to establish an AI innovation lab in the San Francisco Bay area, committing up to $1 billion over five years. The facility will co-locate Eli Lilly’s drug discovery scientists with Nvidia’s AI engineers to develop machine learning models that accelerate target identification, lead optimization and preclinical candidate selection. This builds on Lilly’s prior investments, including last year’s announcement of an industry-leading supercomputer partnership and the launch of its TuneLab platform, positioning the company to reduce the typical decade-long, $1 billion drug development cycle by improving success rates and cutting early-stage attrition.

Eli Lilly recently agreed to acquire Ventyx Biosciences for an undisclosed sum, securing rights to Ventyx’s lead candidate, which targets a novel central nervous system receptor implicated in neurodegenerative disorders. This bolt-on deal adds a preclinical asset to Lilly’s discovery engine and grants exclusive global rights to small-molecule modulators backed by in vitro potency data showing sub-nanomolar activity. Analysts expect the integration to bolster Lilly’s mid-stage pipeline by 2027 and to potentially contribute incremental annual revenues in excess of $500 million if clinical proof of concept is achieved in phase 2 trials.

In the third quarter, Eli Lilly reported revenues of $17.6 billion, up 54% year-over-year, fuelled by sales of tirzepatide under the weight-loss brand Zepbound, which became the world’s top-selling drug that quarter. Adjusted earnings per share reached $6.21, a 480% increase compared to the prior-year period. With orforglipron and retatrutide both advancing in late-stage studies, management forecasts sustained double-digit top-line growth through 2028, assuming regulatory approvals and market uptake progress according to plan.

Regulators have reportedly postponed their decision on Lilly’s oral obesity therapy orforglipron, pushing the target action date into April. The extension provides additional time for review of cardiovascular outcomes trial data but delays potential U.S. market entry. While investors had anticipated a faster approval following the company’s submission last quarter, management emphasized that the delay does not reflect safety concerns and reiterated plans to launch orforglipron alongside retatrutide in key markets once clearance is granted.